Myriad Genetics Inc

MYGNNASDAQUSD
3.16 USD
0.02 (0.47%)🟢LIVE (AS OF 10:06 AM EDT)
🟢Market: OPEN

MYGN is currently priced at $3.16. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, MYGN appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Aug 4, 2026.

Open?$3.12
High?$3.21
Low?$3.07
Prev. Close?$3.17
Volume?344.9K
Avg. Volume?2.1M
VWAP?$3.14
Rel. Volume?0.16x
Bid / Ask
Bid?$3.17 × 500
Ask?$3.18 × 100
Spread?$0.01
Midpoint?$3.18
Valuation & Ratios
Market Cap?303.2M
Shares Out?95.6M
Float?90.9M
Float %?96.2%
P/E Ratio?N/A
P/B Ratio?1.00
EPS?-$1.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Employees
2.7K
Market Cap
288.9M
Industry
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Listed
1995-10-06
Address
322 NORTH 2200 WEST
SALT LAKE CITY, UT 84116
Phone: 801-584-3600
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-3/3)
Medium-Term (Wave)? Bearish(-2/3)
Short-Term (Ripple)? Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
1
Momentum?
17
Short Sent.?
39
Piotroski F-Score?3/9Weak
Altman Z-Score?-1.04Distress
Confidence?67%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?8.81%Elevated
Short Interest?8.0M
Days to Cover?7.3
Free Float90.9M
Avg Daily Volume1.1M
Settlement Date2026-07-15
Financial Health
Current Ratio?2.21Strong
Quick Ratio?1.98Adequate
Cash Ratio?0.88Adequate
Debt/Equity?0.40Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A
P/B?
Peers
100
S&P
97
1.00CHEAP
P/S?
Peers
100
S&P
97
0.38CHEAP
P/FCF?
N/A
EV/EBITDA?
S&P
97
-7.7CHEAP
EV/Sales?
Peers
100
S&P
97
0.38CHEAP
Returns & Efficiency
ROE?
S&P
3
-37.1%WEAK
ROA?
S&P
3
-17.6%WEAK
Cash Flow & Enterprise
FCF?$-7300000
Enterprise Value?$308.7M
Fundamentals ratios updated end of day